PET cardiac imaging
efficient PET myocardial perfusion imaging agents
quantitative imaging of coronary artery disease
cardiovascular disease nuclear imaging
novel biomarker
availability of PET scanners
growing need of non-invasive PET cardiac probes
myocardial blood flow
adoption of Positron Emission Tomography
SPECT cardiac procedures
growing abundance
coronary flow reserve
pre-clinical trials
adverse cardiac events
common form of heart disease
high growth trend
growing business opportunity
Clinical performance validation
diagnostic ability
key stakeholders
reduction of unnecessary invasive downstream procedures
reduction of patientsâ€™ risks
high volume market
reduced radiation doses
number of key players
Diagnostic Partnering deals
projected growth rates
result of numerous advantages
risk of heart attack
shorter period of radiation retention
success of completed synthesis
negotiations
evaluation discovery process
MPI
DMDPA
superior image quality
toxicity tests
Europe
leading cause of death
objective
absolute terms
unique possibility of measuring
CAD
prognostic marker
consultancy
shortage of available
future years
Phase
Western World
economic feasibility assessment
publications
compelling evidence
willingness